Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference

The clinical-stage vaccine innovation company will participate in a fireside chat on April 14, 2026.

Apr. 7, 2026 at 8:34pm

Got story updates? Submit your updates here. ›

An extreme close-up X-ray photograph revealing the intricate, ghostly internal structures of a pneumococcal bacterium, conceptually illustrating Vaxcyte's approach to developing advanced pneumococcal vaccines.Vaxcyte's innovative vaccine candidates target the complex internal structures of deadly pneumococcal bacteria to provide broader protection against invasive disease.San Carlos Today

Vaxcyte, Inc., a clinical-stage vaccine innovation company, announced that the company's management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 2:15 p.m. ET / 11:15 a.m. PT. A live webcast of the fireside chat will be available through the Investors & Media section of Vaxcyte's website.

Why it matters

As a clinical-stage vaccine innovation company, Vaxcyte's participation in major healthcare conferences provides an opportunity to share updates on the development of its pipeline of novel vaccine candidates, including VAX-31, VAX-24, and VAX-XL, which are designed to offer broader protection against pneumococcal disease.

The details

Vaxcyte is developing a portfolio of advanced pneumococcal conjugate vaccine (PCV) candidates, including VAX-31, a 31-valent PCV being evaluated in Phase 3 adult and Phase 2 infant clinical trials, and VAX-24, a 24-valent PCV designed to cover more serotypes than any infant PCV currently on the market. The company's technology platform, XpressCF®, is intended to accelerate the development of high-fidelity vaccines with enhanced immunological benefits.

  • The fireside chat will take place on Tuesday, April 14, 2026 at 2:15 p.m. ET / 11:15 a.m. PT.

The players

Vaxcyte, Inc.

A clinical-stage vaccine innovation company developing advanced pneumococcal conjugate vaccine candidates and leveraging its XpressCF® cell-free protein synthesis platform.

Jeff Macdonald

Executive Director of Investor Relations at Vaxcyte, Inc.

Got photos? Submit your photos here. ›

What they’re saying

“A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company's website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference.”

— Jeff Macdonald, Executive Director, Investor Relations

What’s next

Investors and the public will be able to access the live webcast of Vaxcyte's fireside chat at the 25th Annual Needham Virtual Healthcare Conference on the company's website. A replay of the webcast will also be available for approximately 30 days following the event.

The takeaway

Vaxcyte's participation in the Needham Healthcare Conference provides an opportunity for the company to share updates on the development of its innovative pneumococcal vaccine candidates, which aim to offer broader protection against the disease and its associated complications.